ANVS
Annovis Bio, Inc.
NYSE · Healthcare · Biotechnology · US
$1.39
+0.72%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
Market Cap
$59.22M
MomentumView details →
1D Return
+0.72%
YTD Return
−59.68%
RSI (14)
28.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
Market Cap
$59.22M
RSI (14)
28.7
MomentumView details →
1D Return
+0.72%
YTD Return
−59.68%
SummaryUpdated Jun 1, 2026
Annovis Bio, Inc. (NASDAQ:ANVS) is a clinical-stage biotechnology company founded in 2008 and headquartered in Berwyn, Pennsylvania. The company went public in January 2020 and focuses on developing novel drug treatments for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Annovis operates as a drug platform company, meaning it develops a portfolio of compounds that can potentially treat multiple neurological conditions through similar mechanisms of action.
Similar companies
Latest newsMore news →
ANNOVIS BIO announced that its Phase 3 clinical trial for Alzheimer's disease has completed enrollment of all subjects, with key data and regulatory submission expected in 2027.10d agoAnnovis Bio, Inc. reported its financial results for the second quarter ended June 30, 2026.21d agoAnnovis Bio reached full enrollment in its pivotal Phase 3 trial of buntanetap for early Alzheimer's disease.59d ago